alprazolam has been researched along with Renal Insufficiency, Chronic in 1 studies
Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238)
alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| " If confirmed, this could have major implications for drug dosing in persistently inflamed patients." | 1.38 | Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation. ( Bertilsson, L; Carrero, JJ; Diczfalusy, U; Heimbürger, O; Lindholm, B; Molanaei, H; Odar-Cederlöf, I; Qureshi, AR; Stenvinkel, P, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Molanaei, H | 1 |
| Stenvinkel, P | 1 |
| Qureshi, AR | 1 |
| Carrero, JJ | 1 |
| Heimbürger, O | 1 |
| Lindholm, B | 1 |
| Diczfalusy, U | 1 |
| Odar-Cederlöf, I | 1 |
| Bertilsson, L | 1 |
1 other study available for alprazolam and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation.
Topics: Adult; Aged; Algorithms; Alprazolam; Anti-Anxiety Agents; Biomarkers; Biotransformation; C-Reactive | 2012 |